Please assess the completion status of the following clinical trial:

Trial Title: Synaptic Plasticity and Cognitive Function in RASopathies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Group 1: NS, Group 2: NF1 (both genetically assured)~2. Age ≥16 years~3. The adolescent (≥16) and legal guardian who are capable to give their consent and understand the aim and rationale of the study. In case of doubts, an independent medical practitioner will evaluate the capacity to consent.~4. Signed informed consent if ≥ 16 years and legal guardian.~5. Persons who are ≥ 18 years old and capable to give their consent and understand the aim and rationale of the study. In case of doubts, an independent medical practitioner will evaluate the capacity to consent.~6. Signed informed consent if ≥ 18 years.~7. Male participants and female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country.~Exclusion Criteria:~1. Epilepsy~2. Medication with known CNS effects~3. Severe mental retardation~4. Side effects during previous medication with and contraindications for LTG and/or LOV and/or TMS~5. Psychiatric diseases~6. Previous history of allergic reactions with LTG and LOV medications~7. Potentially unreliable patients~8. Patients who are not suitable for the study in the opinion of the investigator~9. Pregnancy (incl. positive urine pregnancy test)~10. Persons who are incapable of giving consent or do not understand the aim or rationale of the study.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Exp. I: Noonan Syndrome - Lovastatin (Type: EXPERIMENTAL): 200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance
- Exp. II: Noonan Syndrome - Lamotrigine (Type: EXPERIMENTAL): 300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
- Exp. III: Neurofibromatosis Type 1 - Lamotrigine (Type: EXPERIMENTAL): 300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance

Based on this trial design, predict the completion outcome and termination type (if applicable).